Product image of Mvabea (Modified Vaccinia Ankara - Bavarian Nordic Virus Encoding The Ebola Virus Zaire Mayinga Strain Glyco) supplied by GNH India

Mvabea

Active Ingredient:
Modified Vaccinia Ankara - Bavarian Nordic Virus Encoding The Ebola Virus Zaire Mayinga Strain Glyco
Origin:
EU

Mvabea (Modified Vaccinia Ankara - Bavarian Nordic Virus Encoding The Ebola Virus Zaire Mayinga Strain Glyco)

Modified Vaccinia Ankara - Bavarian Nordic Virus Encoding The Ebola Virus Zaire Mayinga Strain Glyco, the active ingredient in Mvabea, is a vaccine presented as a sterile suspension for intramuscular use. It is intended to prevent Ebola virus disease caused by the Zaire ebolavirus in at‑risk populations.
GNH India supplies Mvabea as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Janssen-Cilag International Nv

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mvabea is a viral‑vector vaccine used within the Ebola virus disease prevention pathway.

  • Prevention of Ebola virus disease (EVD): induces immunity to protect against Zaire ebolavirus infection.
  • Outbreak response: provides rapid immunisation for contacts of confirmed Ebola cases during an outbreak.
  • Healthcare‑worker protection: reduces occupational risk for staff caring for Ebola patients.

How It Works

  • Mvabea delivers the glycoprotein of the Zaire ebolavirus Mayinga strain via a replication‑deficient Modified Vaccinia Ankara (MVA) vector. The expressed glycoprotein is presented to the immune system, stimulating both neutralising antibody production and cellular T‑cell responses, thereby establishing protective immunity against Ebola virus infection.

Side Effects

Mvabea is generally well tolerated, but adverse reactions can occur.

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Redness or swelling: localized erythema or edema.
  • Fever: transient elevation of body temperature.
  • Headache: mild to moderate headache.
  • Fatigue: temporary feeling of tiredness.
  • Myalgia: muscle aches.

Serious or Rare Side Effects

  • Severe allergic reaction: anaphylaxis requiring immediate medical attention.
  • Neurological events: rare cases of encephalitis or seizures.
  • Thrombocytopenia: low platelet count observed in isolated reports.
  • Autoimmune phenomena: very rare onset of autoimmune disorders.
  • Cardiac events: rare myocarditis or pericarditis.
  • Disseminated infection: extremely rare uncontrolled viral replication.

Precautions & Warnings

Mvabea should be administered by qualified healthcare professionals following standard vaccination protocols.

  • Contraindication: known severe allergy to any vaccine component.
  • Caution: immunocompromised individuals may have altered response; monitor closely.
  • Pregnancy: safety not established; weigh potential benefits against unknown risks.
  • Breastfeeding: limited data; consider risk‑benefit assessment.
  • Interaction with live vaccines: avoid administering other live vaccines within 4 weeks.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Mvabea may interact with other immunological agents, requiring careful management.

Major Interactions (Avoid)

  • Live attenuated vaccines: concurrent use can compromise efficacy of either product.
  • High‑dose immunoglobulin therapy: may neutralise vaccine vector.

Moderate Interactions (Monitor Closely)

  • Immunosuppressive drugs: may reduce vaccine‑induced immunity.
  • Antiviral agents targeting poxviruses: could interfere with vector replication.
  • Cytokine therapies: potential for exaggerated immune response.
  • Hematopoietic stem cell transplantation: timing should be coordinated with transplant schedule.

Frequently Asked Questions

Mvabea is a vaccine indicated for the prevention of Ebola virus disease caused by the Zaire ebolavirus. It is used to protect individuals at risk of exposure, including during outbreaks and for healthcare workers caring for Ebola patients.

The Modified Vaccinia Ankara (MVA) vector in Mvabea carries the gene for the Ebola virus glycoprotein. After intramuscular injection, the vector expresses this protein, prompting the immune system to generate both antibodies and T‑cell responses that target the Ebola virus.

The dosing regimen for Mvabea is determined by the prescribing clinician based on current guidelines and the patient’s risk profile. Healthcare providers set the number of doses and interval between administrations.

Safety data for Mvabea in pregnancy and lactation are limited. The vaccine should only be administered when the potential benefit justifies any unknown risk, and the decision should be made by a qualified healthcare professional.

To order Mvabea, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Mvabea uses a replication‑deficient MVA vector, whereas some alternatives employ adenovirus or recombinant protein platforms. The MVA approach offers a strong safety profile and robust cellular immunity, but comparative effectiveness depends on specific trial data and population characteristics.

Mvabea must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Maintain the cold chain during transport and handling to preserve vaccine potency.

Mvabea is given as a single intramuscular injection, typically into the deltoid muscle. Administration should be performed by trained healthcare personnel following standard aseptic techniques.

Serious risks include severe allergic reactions such as anaphylaxis, rare neurological events like encephalitis, and very uncommon autoimmune or cardiac complications. Prompt medical evaluation is required if any severe symptoms develop after vaccination.

Individuals with a known severe allergy to any component of the vaccine, or those who have experienced a serious adverse reaction to a previous dose of Mvabea, should not receive the vaccine. Consultation with a healthcare professional is essential for other contraindications.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Modified Vaccinia Ankara - Bavarian Nordic Virus Encoding The Ebola Virus Zaire Mayinga Strain Glyco

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT